Sugi Predict

Sugi Predict / Compounds / SCHEMBL3207274

SCHEMBL3207274

SCHEMBL3207274

COC[C@@H]1CN(Cc2cc(F)cc(NC(=O)Nc3ccc(C)nc3)c2)CCN1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 1/20 0.39
▸ HTR1A P08908 2/20 0.36
▸ HTR1D P28221 2/20 0.36
▸ HTR1B P28222 2/20 0.36
▸ CCR3 P51677 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ ADRB2 P07550 1/20 0.36
▸ S1PR1 P21453 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GALR3 O60755 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ BRAF P15056 2/20 0.35
▸ KDR P35968 2/20 0.35
▸ MAPK8 P45983 2/20 0.35
▸ MAPK10 P53779 2/20 0.35
▸ FPR1 P21462 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ CCR1 P32246 2/20 0.35
▸ FPR3 P25089 1/20 0.35
▸ GPR65 Q8IYL9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29714052 0.93 RORC (0.40) RORCCCR3CYP1A2ADRB2GRIN2B
SCHEMBL3196588 0.89 CYP1A2 (0.46) HTR1ACYP1A2
SCHEMBL3201129 0.87 RORC (0.48) RORCCCR1FPR3GPR65GPR35
SCHEMBL3208975 0.87 RAB9A (0.39) RORCCCR3GALR3RAB9AMAPK8
SCHEMBL3204584 0.87 RAB9A (0.39) RORCCCR3GALR3RAB9AMAPK8
SCHEMBL397923 0.86 CYP1A2 (0.38) RORCCCR3CYP1A2ADRB2GRIN2B
SCHEMBL399214 0.85 CYP1A2 (0.44) RORCCCR3CYP1A2ADRB2GRIN2B
SCHEMBL3198421 0.82 RORC (0.40) RORCHTR1AHTR1DHTR1BCCR3
SCHEMBL3200015 0.82 RORC (0.40) RORCHTR1AHTR1DHTR1BCCR3
SCHEMBL29714046 0.82 CYP1A2 (0.46) HTR1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-8445495-B2 Certain Chemical entities, compositions and methods CYTOKINETICS, INC. (US) 2013-05-21 — — US disclosed
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-02-04 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 RORC 2972/4885HTR1A 4023/4885HTR1D 4122/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 RORC 4016/4885HTR1A 2635/4885HTR1D 2382/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20100029680-A1 Certain Chemical Entities, Compositions and Methods TNNI3, TNNT2, MYLK2 RORC 2972/4885HTR1A 4023/4885HTR1D 4122/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RORC 3759/4885HTR1A 3992/4885HTR1D 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.